Amyloid‐β PET in Alzheimer's disease: A systematic review and Bayesian meta‐analysis

In recent years, longitudinal studies of Alzheimer's disease (AD) have been successively concluded. Our aim is to determine the efficacy of amyloid‐β (Aβ) PET in diagnosing AD and early prediction of mild cognitive impairment (MCI) converting to AD. By pooling studies from different centers to explore in‐depth whether diagnostic performance varies by population type, radiotracer type, and diagnostic approach, thus providing a more comprehensive theoretical basis for the subsequent widespread application of Aβ PET in the clinical setting.

[1]  R. Nixon,et al.  Faulty autolysosome acidification in Alzheimer’s disease mouse models induces autophagic build-up of Aβ in neurons, yielding senile plaques , 2022, Nature Neuroscience.

[2]  L. Schneider,et al.  High cerebrospinal amyloid-β 42 is associated with normal cognition in individuals with brain amyloidosis , 2021, EClinicalMedicine.

[3]  L. Ferrucci,et al.  Effects of monoclonal antibodies against amyloid-β on clinical and biomarker outcomes and adverse event risks: A systematic review and meta-analysis of phase III RCTs in Alzheimer’s disease , 2021, Ageing Research Reviews.

[4]  A. Kesselheim,et al.  Evaluation of Aducanumab for Alzheimer Disease: Scientific Evidence and Regulatory Review Involving Efficacy, Safety, and Futility. , 2021, JAMA.

[5]  E. Mayo-Wilson,et al.  The PRISMA 2020 statement: an updated guideline for reporting systematic reviews , 2021, BMJ.

[6]  Anonymous,et al.  2021 Alzheimer's disease facts and figures , 2021, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[7]  K. Abe,et al.  Clinical impact of 11C-Pittsburgh compound-B positron emission tomography in addition to magnetic resonance imaging and single-photon emission computed tomography on diagnosis of mild cognitive impairment to Alzheimer's disease , 2021, Medicine.

[8]  D. Y. Lee,et al.  Performance of the QPLEX™ Alz plus assay, a novel multiplex kit for screening cerebral amyloid deposition , 2021, Alzheimer's Research & Therapy.

[9]  Chotipanich Chanisa,et al.  Analysis of amyloid and tau deposition in Alzheimer's disease using 11C-Pittsburgh compound B and 18F-THK 5351 positron emission tomography imaging , 2020, World journal of nuclear medicine.

[10]  D. Y. Lee,et al.  Performance of the QPLEX™ Alz plus assay, a novel multiplex kit for screening cerebral amyloid deposition , 2020, Alzheimer's research & therapy.

[11]  C. DeCarli,et al.  Diagnostic Accuracy of Amyloid versus 18F‐Fluorodeoxyglucose Positron Emission Tomography in Autopsy‐Confirmed Dementia , 2020, Annals of Neurology.

[12]  M. Sabbagh,et al.  Aducanumab, gantenerumab, BAN2401, and ALZ-801—the first wave of amyloid-targeting drugs for Alzheimer’s disease with potential for near term approval , 2020, Alzheimer's Research & Therapy.

[13]  D. Y. Lee,et al.  Prognostic plasma protein panel for Aβ deposition in the brain in Alzheimer’s disease , 2019, Progress in Neurobiology.

[14]  M. Politis,et al.  Applications of amyloid, tau, and neuroinflammation PET imaging to Alzheimer's disease and mild cognitive impairment , 2019, Human brain mapping.

[15]  H. Struyfs,et al.  Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and 18F-FDG-PET imaging , 2019, NeuroImage: Clinical.

[16]  C. Jack,et al.  Multisite study of the relationships between antemortem [11C]PIB-PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology , 2018, Alzheimer's & Dementia.

[17]  R. Boellaard,et al.  Diagnostic performance of regional cerebral blood flow images derived from dynamic PIB scans in Alzheimer’s disease , 2019, EJNMMI Research.

[18]  Francisco P M Oliveira,et al.  Data driven diagnostic classification in Alzheimer's disease based on different reference regions for normalization of PiB-PET images and correlation with CSF concentrations of Aβ species , 2018, NeuroImage: Clinical.

[19]  Olivier Salvado,et al.  Implementing the centiloid transformation for 11C-PiB and β-amyloid 18F-PET tracers using CapAIBL , 2018, NeuroImage.

[20]  C. Jack,et al.  Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau- and amyloid-positron emission tomography , 2018, Alzheimer's & Dementia.

[21]  P. Pástor,et al.  Clinic-Based Validation of Cerebrospinal Fluid Biomarkers with Florbetapir PET for Diagnosis of Dementia. , 2017, Journal of Alzheimer's disease : JAD.

[22]  N. Zhang,et al.  Urine AD7c-NTP Predicts Amyloid Deposition and Symptom of Agitation in Patients with Alzheimer’s Disease and Mild Cognitive Impairment , 2017, Journal of Alzheimer's disease : JAD.

[23]  P. Payoux,et al.  Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer’s disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database , 2017, Alzheimer's Research & Therapy.

[24]  Kazunari Ishii,et al.  Validation of a New Imaging Technique Using the Glucose Metabolism to Amyloid Deposition Ratio in the Diagnosis of Alzheimer's Disease. , 2017, Current Alzheimer research.

[25]  Sang Won Seo,et al.  Regional correlations between [11C]PIB PET and post-mortem burden of amyloid-beta pathology in a diverse neuropathological cohort , 2016, NeuroImage: Clinical.

[26]  D. Perani,et al.  A Cross-Validation of FDG- and Amyloid-PET Biomarkers in Mild Cognitive Impairment for the Risk Prediction to Dementia due to Alzheimer's Disease in a Clinical Setting. , 2017, Journal of Alzheimer's disease : JAD.

[27]  Vincent Doré,et al.  Standardized Expression of 18F-NAV4694 and 11C-PiB β-Amyloid PET Results with the Centiloid Scale , 2016, The Journal of Nuclear Medicine.

[28]  L. Wilkins.  Use of amyloid-PET to determine cutpoints for CSF markers: A multicenter study , 2016, Neurology.

[29]  Yun Zhou,et al.  Potential Clinical Value of Multiparametric PET in the Prediction of Alzheimer’s Disease Progression , 2016, PloS one.

[30]  Fabio Sambataro,et al.  Accurate Prediction of Conversion to Alzheimer's Disease using Imaging, Genetic, and Neuropsychological Biomarkers. , 2015, Journal of Alzheimer's disease : JAD.

[31]  A. Hammers,et al.  Diagnostic accuracy of (18)F amyloid PET tracers for the diagnosis of Alzheimer's disease , 2016 .

[32]  L. Yao,et al.  Multimodal Classification of Mild Cognitive Impairment Based on Partial Least Squares. , 2016, Journal of Alzheimer's disease : JAD.

[33]  L. Yao,et al.  Prediction of Progressive Mild Cognitive Impairment by Multi-Modal Neuroimaging Biomarkers. , 2016, Journal of Alzheimer's disease : JAD.

[34]  Young Ho Park,et al.  Analysis of Cerebrospinal Fluid and [11C]PIB PET Biomarkers for Alzheimer's Disease with Updated Protocols. , 2016, Journal of Alzheimer's disease : JAD.

[35]  P. Tariot,et al.  Detection of Amyloid β Signature in the Lens and Its Correlation in the Brain to Aid in the Diagnosis of Alzheimer’s Disease , 2015, American journal of Alzheimer's disease and other dementias.

[36]  Stefanie Schreiber,et al.  Comparison of Visual and Quantitative Florbetapir F 18 Positron Emission Tomography Analysis in Predicting Mild Cognitive Impairment Outcomes. , 2015, JAMA neurology.

[37]  Charles DeCarli,et al.  Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation. , 2015, Brain : a journal of neurology.

[38]  Robert A. Koeppe,et al.  The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET , 2015, Alzheimer's & Dementia.

[39]  Joanne S. Robertson,et al.  Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study. , 2015, Journal of Alzheimer's disease : JAD.

[40]  Takamichi Murakami,et al.  Investigation of 11C-PiB equivocal PET findings , 2015, Annals of Nuclear Medicine.

[41]  A. Nakamura,et al.  Novel plasma biomarker surrogating cerebral amyloid deposition , 2014, Proceedings of the Japan Academy. Series B, Physical and biological sciences.

[42]  D. Rujescu,et al.  Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease. , 2014, JAMA psychiatry.

[43]  W. Kukull,et al.  Theoretical Impact of Florbetapir (18F) Amyloid Imaging on Diagnosis of Alzheimer Dementia and Detection of Preclinical Cortical Amyloid , 2014, Journal of neuropathology and experimental neurology.

[44]  M. Ewers,et al.  Distinct pattern of hypometabolism and atrophy in preclinical and predementia Alzheimer's disease , 2014, Neurobiology of Aging.

[45]  Ming-Jang Chiu,et al.  Plasma Aβ but not tau is related to brain PiB retention in early Alzheimer's disease. , 2014, ACS chemical neuroscience.

[46]  Philip S. Insel,et al.  Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease , 2014, Annals of clinical and translational neurology.

[47]  L. Thurfjell,et al.  Amyloid PET imaging in Alzheimer’s disease: a comparison of three radiotracers , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[48]  P. Trzepacz,et al.  Comparison of neuroimaging modalities for the prediction of conversion from mild cognitive impairment to Alzheimer's dementia , 2013, Neurobiology of Aging.

[49]  P. Payoux,et al.  Comparison between PET template-based method and MRI-based method for cortical quantification of florbetapir (AV-45) uptake in vivo , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[50]  H. Arrighi,et al.  Rate of Conversion from Prodromal Alzheimer's Disease to Alzheimer's Dementia: A Systematic Review of the Literature , 2013, Dementia and Geriatric Cognitive Disorders Extra.

[51]  S. Hatashita,et al.  Diagnosed Mild Cognitive Impairment Due to Alzheimer’s Disease with PET Biomarkers of Beta Amyloid and Neuronal Dysfunction , 2013, PloS one.

[52]  Kingshuk Roy Choudhury,et al.  Predicting cognitive decline in subjects at risk for Alzheimer disease by using combined cerebrospinal fluid, MR imaging, and PET biomarkers. , 2013, Radiology.

[53]  C. Jack,et al.  Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers , 2013, The Lancet Neurology.

[54]  Patrick M. M. Bossuyt,et al.  Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy , 2013 .

[55]  Lucie Yang,et al.  Brain amyloid imaging--FDA approval of florbetapir F18 injection. , 2012, The New England journal of medicine.

[56]  C. Jack,et al.  An operational approach to National Institute on Aging–Alzheimer's Association criteria for preclinical Alzheimer disease , 2012, Annals of neurology.

[57]  A. Alavi,et al.  Initial Clinical Comparison of 18F-Florbetapir and 18F-FDG PET in Patients with Alzheimer Disease and Controls , 2012, The Journal of Nuclear Medicine.

[58]  Ramin V. Parsey,et al.  Multimodal classification of Dementia using functional data, anatomical features and 3D invariant shape descriptors , 2012, 2012 9th IEEE International Symposium on Biomedical Imaging (ISBI).

[59]  B. Vellas,et al.  Using PET with 18F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[60]  J. Kornak,et al.  Amyloid Vs Fdg-pet in the Differential Diagnosis of Ad And , 2022 .

[61]  Kewei Chen,et al.  Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. , 2011, Archives of neurology.

[62]  Susan Mallett,et al.  QUADAS-2: A Revised Tool for the Quality Assessment of Diagnostic Accuracy Studies , 2011, Annals of Internal Medicine.

[63]  C. Rowe,et al.  Amyloid Imaging with 18F-Florbetaben in Alzheimer Disease and Other Dementias , 2011, The Journal of Nuclear Medicine.

[64]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease: Report of the NINCDS—ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease , 2011, Neurology.

[65]  Nick C Fox,et al.  The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[66]  Denise C. Park,et al.  Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[67]  M. Albert,et al.  Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[68]  E. Salmon,et al.  18F‐flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial , 2010, Annals of neurology.

[69]  Lars Farde,et al.  Characterization of AZD4694, a novel fluorinated Aβ plaque neuroimaging PET radioligand , 2010, Journal of neurochemistry.

[70]  H. Hall,et al.  [(11)C]PIB-amyloid binding and levels of Abeta40 and Abeta42 in postmortem brain tissue from Alzheimer patients , 2010, Alzheimer's & Dementia.

[71]  W. M. van der Flier,et al.  Molecular imaging in the diagnosis of Alzheimer's disease: visual assessment of [11C]PIB and [18F]FDDNP PET images , 2010, Journal of Neurology, Neurosurgery & Psychiatry.

[72]  C. Rowe,et al.  11C-PIB binding is increased in patients with cerebral amyloid angiopathy–related hemorrhage , 2010, Neurology.

[73]  Nick C Fox,et al.  The clinical use of structural MRI in Alzheimer disease , 2010, Nature Reviews Neurology.

[74]  Nick C Fox,et al.  Conversion of amyloid positive and negative MCI to AD over 3 years , 2009, Neurology.

[75]  L. Thurfjell,et al.  Phase 1 Study of the Pittsburgh Compound B Derivative 18F-Flutemetamol in Healthy Volunteers and Patients with Probable Alzheimer Disease , 2009, Journal of Nuclear Medicine.

[76]  Bengt Långström,et al.  [11C]PIB-amyloid binding and levels of Aβ40 and Aβ42 in postmortem brain tissue from Alzheimer patients , 2009, Neurochemistry International.

[77]  Marie-Claude Potier,et al.  Classification and basic pathology of Alzheimer disease , 2009, Acta Neuropathologica.

[78]  Y. Yuan,et al.  Fluorodeoxyglucose–Positron-Emission Tomography, Single-Photon Emission Tomography, and Structural MR Imaging for Prediction of Rapid Conversion to Alzheimer Disease in Patients with Mild Cognitive Impairment: A Meta-Analysis , 2008, American Journal of Neuroradiology.

[79]  Linda S Hynan,et al.  Clinical criteria for the diagnosis of Alzheimer disease: still good after all these years. , 2008, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[80]  S. DeKosky,et al.  Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease , 2008, Brain : a journal of neurology.

[81]  P. Scheltens,et al.  Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria , 2007, The Lancet Neurology.

[82]  Christopher C Rowe,et al.  Visual Assessment Versus Quantitative Assessment of 11C-PIB PET and 18F-FDG PET for Detection of Alzheimer's Disease , 2007, Journal of Nuclear Medicine.

[83]  S. Riedel-Heller,et al.  Mild cognitive impairment , 2006, Neurology.

[84]  S. Lovestone,et al.  IsMCI really just early dementia ? A systematic reviewof conversion studies , 2004 .

[85]  et al.,et al.  Discrimination between Alzheimer Dementia and Controls by Automated Analysis of Multicenter FDG PET , 2002, NeuroImage.

[86]  J. Morris,et al.  Tangles and plaques in nondemented aging and “preclinical” Alzheimer's disease , 1999, Annals of neurology.

[87]  W. Markesbery.  Neuropathological Criteria for the Diagnosis of Alzheimer’s Disease , 1997, Neurobiology of Aging.

[88]  C. Bell.  DSM-IV Guidebook , 1995 .

[89]  M. Dahmer,et al.  Insulin‐Like Growth Factor‐I Enhances Tyrosine Hydroxylase Activation in Bovine Chromaffin Cells , 1991, Journal of neurochemistry.

[90]  S. M. Sumi,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) , 1991, Neurology.

[91]  V. Hachinski,et al.  A NEW DEFINITION OF ALZHEIMER'S DISEASE: A HIPPOCAMPAL DEMENTIA , 1985, The Lancet.